Date: 2015-03-19
Type of information: Licensing agreement
Compound: anti-tau antibodies
Company: AbbVie (USA - IL) C2N Diagnostics (USA - MO)
Therapeutic area: Neurodegenerative diseases - Neurological diseases
Type agreement: licensing
Action mechanism: atibody
Disease: Alzheimer\'s disease and other neurological disorders
Details: * On March 19, 2015, AbbVie announced that it has entered into an exclusive worldwide license agreement with C2N Diagnostics, a privately held protein diagnostic and therapeutic discovery company, to develop and commercialize a portfolio of anti-tau antibodies for the treatment of Alzheimer\'s Disease and other neurological disorders. This partnership builds upon AbbVie\'s commitment to pursue transformational disease-modifying therapies in Alzheimer\'s Disease. Abnormal accumulation of altered tau protein is a leading indicator in a variety of neurodegenerative conditions including Alzheimer\'s Disease, Progressive Supranuclear Palsy and Corticobasal Degeneration. In these conditions, the development of tau pathology strongly correlates with clinical disease progression. \"C2N\'s portfolio of anti-tau antibodies represents one of the most promising approaches to delaying progression of devastating neurodegenerative disease. Combining the world class expertise in Alzheimer\'s Disease at C2N with AbbVie\'s proven capabilities in neuroscience will enable the rapid advancement of anti-tau antibodies into patients,\"said Jim Sullivan, Ph.D., vice president, pharmaceutical discovery, AbbVie.
Financial terms: Financial terms of the collaboration were not disclosed.
Latest news:
